The FDA regularly approves Enfortumab Wedotin-ejfv for the treatment of locally advanced or metastatic urothelial carcinoma 20/06/2022 Urothelial cancer PD-L1 gene, PD-1 gene
FDA accelerates approval of Sacituzumab Govitecan-hziy for the treatment of advanced urethral epithelial cancer 20/06/2022 Urothelial cancer PD-L1 gene
The total survival period of urothelial cancer has been significantly extended! ADC new drug Padcev approved to expand indications 20/06/2022 Urothelial cancer PD-L1 gene
What medicine to use after urothelial carcinoma is resistant to drugs? ADC drug Padcev significantly improves survival 20/06/2022 Urothelial cancer PD-L1 gene
Nemesis of chemotherapy resistance for urothelial cancer! Immunotherapy Avilumab has a significant effect on the first-line maintenance treatment of avilumab 20/06/2022 Urothelial cancer PD-L1 gene
FDA accelerates approval of erdafitinib for the treatment of metastatic urothelial cancer 15/06/2022 Urothelial cancer FGFR gene
The first targeted therapy for metastatic urothelial cancer! Urdatinib Balversa has a significant clinical effect 15/06/2022 Urothelial cancer FGFR gene
FDA accelerates approval of Sacituzumab Govitecan-hziy for the treatment of advanced urethral epithelial cancer 09/06/2022 Urethral epithelial cancer PD-1 /PD-L1
The first targeted therapy for metastatic urothelial cancer! Urdatinib Balversa has a significant clinical effect 09/06/2022 Metastatic urothelial cancer FGFR
The total survival period of urothelial cancer has been significantly extended! ADC new drug Padcev approved to expand indications 09/06/2022 Urothelial cancer EGFR
